Free Trial
NASDAQ:HSTO

Histogen (HSTO) Stock Price, News & Analysis

Histogen logo
$0.22 0.00 (0.00%)
(As of 11/15/2024 ET)

About Histogen Stock (NASDAQ:HSTO)

Key Stats

Today's Range
$0.22
$0.22
50-Day Range
$0.21
$0.30
52-Week Range
$0.05
$0.55
Volume
426 shs
Average Volume
868 shs
Market Capitalization
$920,000.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Histogen Inc., a clinical-stage therapeutics company, focuses on developing clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body's natural process to restore immune function. The company's product candidates include emricasan for the treatment of acute bacterial skin and skin structure infections, as well as other infectious diseases. Its preclinical product candidates include CTS-2090 and CTS-2096, which are selective small molecule inhibitors of caspase-1 designed for the treatment of various inflammatory diseases. Histogen Inc. was founded in 2007 and is based in San Diego, California. On April 18, 2024, Histogen Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of California.

Receive HSTO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Histogen and its competitors with MarketBeat's FREE daily newsletter.

HSTO Stock News Headlines

Financial Prophecy
The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.
Histogen Files For Voluntary Chapter 11 Bankruptcy Protection
See More Headlines

HSTO Stock Analysis - Frequently Asked Questions

Histogen's stock was trading at $0.3077 at the start of the year. Since then, HSTO shares have decreased by 30.1% and is now trading at $0.2150.
View the best growth stocks for 2024 here
.

Histogen Inc. (NASDAQ:HSTO) announced its quarterly earnings data on Wednesday, November, 10th. The company reported ($1.80) EPS for the quarter, beating analysts' consensus estimates of ($2.20) by $0.40. The company earned $0.59 million during the quarter.

Shares of Histogen reverse split before market open on Friday, June 3rd 2022. The 1-20 reverse split was announced on Friday, June 3rd 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 3rd 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Shares of HSTO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Histogen investors own include Palantir Technologies (PLTR), Tesla (TSLA), Bionano Genomics (BNGO), Applied Genetic Technologies (AGTC), HubSpot (HUBS), Meta Platforms (META) and TherapeuticsMD (TXMD).

Company Calendar

Last Earnings
11/10/2021
Today
11/15/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:HSTO
Fax
N/A
Employees
7
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$3.77 million
Book Value
$3.13 per share

Miscellaneous

Free Float
N/A
Market Cap
$920,000.00
Optionable
Not Optionable
Beta
1.19
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:HSTO) was last updated on 11/15/2024 by MarketBeat.com Staff
From Our Partners